Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group.
By P. Meyers, C. Schwartz, M. Krailo, J. Healey, M. Bernstein, D. Betcher, W. Ferguson, M. Gebhardt, A. Goorin, M. Harris and 9 more. Journal of Clinical Oncology, 2008
713 citations recorded by the source corpus.
Subfields: Molecular Biology, Oncology, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/7e3fb7a545a68fc6f8e158d480eaac263ec18bc8
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Molecular Biology
- Wahid Khan
- Paul S. Meltzer
- H. Stunnenberg
- Ramnik J. Xavier
- G. Natoli
- E. Latz
- Sindhu Doppalapudi
- Luke A. O'Neill
In Oncology
Citations in the corpus
- Osteosarcoma: Current Treatment and a Collaborative Pathway to Success. (2015, background): “However, additional follow-up and use of an overall survival end point suggested no evidence of such an interaction, and a significant improvement in overall survival was observed for patients receiving mifamurtide, regardless of chemotherapy regimen.(29) This has created significant controversy, an”
- Current and future therapeutic approaches for osteosarcoma (2018, background): “Specifically, the addition of MTP-PE to MAP adjuvant therapy led to a trend toward improved EFS as well as an improved overall survival [27,39].”
- Trained immunity: a program of innate immune memory in health and disease (2016, background): “Finally, the concept of innate immune memory has considerable potential in helping the design of novel therapeutic approaches, with at least three potential lines of investigation: (1) the design of new generation vaccines that combine adaptive and innate immune memory, as recently proposed with a n”
- Liposomal Formulations in Clinical Use: An Updated Review (2017, background): “A phase III clinical trial of L-MTP-PE given in addition to the usual combination chemotherapy conducted in children and young adults with osteogenic sarcoma showed an increase in six-year net survival from 70% to 78% [38].”